Nusinersen (SpinrazaTM)

Pages in this website section last updated 17th September

Recent Headlines

17th September 2021
Biogen to Start New Trial to Evaluate Higher Doses of Nusinersen in Later-Onset SMA

12th May 2021
Which Centres are Providing Nusinersen and / or Risdiplam?

10th May 2021
New Guidelines To Improve Access To Nusinersen At Centres

Scroll down further for:

  • What is it?
  • How it works
  • UK Access Now
  • Treatment Information Leaflets
  • Clinical Trials and 'Real World' Use
  • Global Access
  • The Road to UK Access: Autumn 2016 – May 2021

What is it?

In collaboration with researchers, nusinersen was developed by Ionis Pharmaceuticals and Biogen Idec. Marketed as SpinrazaTM, it was the first potentially disease-modifying treatment available in the UK for 5q SMA, which includes SMA Type 1, 2 3 and 4. It is an antisense oligonucleotide designed to modify the product of the SMN2 “backup” gene to produce more functional SMN protein.

You can read how the original scientists who worked on it won the 2019 Breakthrough prize (the “Oscars for science”) here; how Biogen won the UK Prix Galien award for it, here.

How it Works

You can read more and watch Cold Spring Harbor laboratory’s video about how it works, here.

UK Access Now

The NHS now funds this treatment for all children and adults for whom it is clinically safe and potentially beneficial.

Read more

Treatment Information Leaflets

These leaflets aim to provide a summary for anyone considering the possibility of treatment for their child, or themselves. Read More.

Clinical Trial Results and 'Real World' Use

Clinical trials have been with infants and children who have SMA Types 1, 2 or 3. There have not yet been any clinical 
trials with anyone with adult onset SMA Type 4.

Our Research Correspondents have tracked the results as they have been released. You can read these updates 
here. They also summarise published ‘real world’ studies, 
here

Global Access

On 23rd December 2016, the US Food and Drug Administration (FDA) approved the use of nusinersen under its brand name SpinrazaTM for both children and adults with SMA Types 1, 2 or 3 SMA.

On 1st June 2017, the European Commission approved the treatment for those with 5q SMA. Their full report is here. Since then, access in each country has been, and still is being, decided by their regulatory authorities.

You can find out what progress countries have made here.

The Road to UK Access: Autumn 2016 – May 2021

You can read about this long and stressful journey for the SMA Community: Autumn 2016 – July 2019 and August 2019 – May 2021.

FIND OUT WHAT STAGE OTHER DRUGS HAVE REACHED IN OUR DRUG PIPELINE